Shares of OpGen Inc (NASDAQ:OPGN) fell 7.1% on Tuesday . The stock traded as low as $2.05 and last traded at $2.08. 1,560,008 shares changed hands during trading, an increase of 198% from the average session volume of 522,657 shares. The stock had previously closed at $2.24.

Several brokerages have weighed in on OPGN. Zacks Investment Research cut shares of OpGen from a “buy” rating to a “hold” rating in a research note on Wednesday, January 10th. HC Wainwright upped their price objective on shares of OpGen to $9.00 and gave the stock a “buy” rating in a research note on Wednesday, February 7th. Finally, ValuEngine raised shares of OpGen from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.

The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.13 and a current ratio of 1.23. The stock has a market cap of $10.23, a P/E ratio of -0.14 and a beta of 0.71.

An institutional investor recently bought a new position in OpGen stock. Perkins Capital Management Inc. purchased a new stake in shares of OpGen Inc (NASDAQ:OPGN) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,400,000 shares of the medical research company’s stock, valued at approximately $434,000. Perkins Capital Management Inc. owned about 2.72% of OpGen at the end of the most recent reporting period.

WARNING: This article was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at

OpGen Company Profile

OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with's FREE daily email newsletter.